Nasdaq:BDTX
Black Diamond Therapeutics, Inc.
A specialized biotech firm targeting rare disease indications with a focus on advancing high-value therapeutic candidates through the clinical pipeline.
Key Metrics
Investment Thesis
Bull Case
Investors may find value in Black Diamond due to its focus on high-value rare disease assets with potential for blockbuster profiles once approved and the possibility of future milestone payments or equity financing that could extend its runway beyond current cash levels.
Bear Case
The stock faces substantial headwinds from a lack of commercial revenue, an annualized cash burn rate that is unsustainable without continuous dilution through share issuances, and the inherent high risk of clinical trial failure typical for clinical-stage biotechnology companies.
About Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics is a clinical-stage biotechnology company focused on developing novel therapeutic candidates for rare diseases, leveraging its proprietary platform to advance pipeline assets through preclinical and clinical development stages.
Analysis
Management Discussion
The company reported a net loss of $69.7M for the latest period, reflecting its strategic heavy investment in research and development of $51.3M alongside general and administrative expenses of $27.5M, resulting in a significant reduction in cash reserves from $57.0M to $36.4M.
Industry Overview
The rare disease therapeutic market represents a high-growth sector with increasing demand for innovative treatments addressing orphan indications, though it remains capital intensive with long development timelines and significant regulatory hurdles before generating commercial income.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 |
| Operating Expenses | $92.8M | $86.5M | $78.8M |
| Operating Income | $-92.8M | $-86.5M | $-78.8M |
| R&D | $64.4M | $59.4M | $51.3M |
| G&A | $28.4M | $27.1M | $27.5M |
| Stock-Based Comp | $12.2M | $9.6M | $10.6M |
| Depreciation | $508.0K | $437.0K | $343.0K |
| Other OpEx | $0 | $0 | $0 |
| Non-Operating Income | $1.6M | $3.8M | $9.1M |
| Pre-Tax Income | $-91.3M | $-82.6M | $-69.7M |
| Income Tax | $0 | $0 | $0 |
| Continuing Ops | $-91.3M | $-82.6M | $-69.7M |
| Discontinued Ops | $101.0K | $197.0K | $0 |
| Net Income | $-91.2M | $-82.4M | $-69.7M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-91.2M | $-82.4M | $-69.7M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $127.7M | $134.0M | $101.2M |
| Cash & Equivalents | $34.3M | $56.2M | $36.4M |
| Prepaid Expenses | $4.9M | $2.6M | $2.6M |
| Other Current Assets | $88.5M | $75.2M | $62.1M |
| Long-Term Assets | $28.5M | $24.5M | $21.5M |
| PP&E (Net) | $2.6M | $1.7M | $1.4M |
| Operating Leases | $24.8M | $22.0M | $19.0M |
| Other LT Assets | $1.2M | $823.0K | $1.1M |
| Total Assets | $156.3M | $158.6M | $122.6M |
| Current Liabilities | $15.3M | $19.6M | $20.6M |
| Accounts Payable | $1.9M | $2.3M | $4.0M |
| Current Leases | $2.8M | $3.1M | $3.4M |
| Other Current Liab | $-2.8M | $-3.1M | $-3.4M |
| Long-Term Liabilities | $25.3M | $22.2M | $18.8M |
| LT Operating Leases | $25.3M | $22.2M | $18.8M |
| Other LT Liab | $0 | $0 | $0 |
| Total Liabilities | $40.6M | $41.8M | $39.4M |
| Shareholders' Equity | $115.7M | $116.7M | $83.3M |
| Paid-In Capital | $452.5M | $534.2M | $570.4M |
| Retained Earnings | $-335.0M | $-417.4M | $-487.1M |
| AOCI | $-1.8M | $-27.0K | $24.0K |
| Total L&E | $156.3M | $158.6M | $122.6M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-91.2M | $-82.4M | $-69.7M |
| Non-Cash Adjustments | $15.2M | $13.5M | $6.2M |
| Working Capital Changes | $-9.1M | $2.3M | $1.1M |
| Cash from Operations | $-85.1M | $-66.7M | $-62.3M |
| Capital Expenditures | $192.0K | $33.0K | $0 |
| Cash from Investing | $53.4M | $16.3M | $17.0M |
| Cash from Financing | $177.0K | $71.9M | $25.5M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-31.5M | $21.6M | $-19.8M |
| Beginning Cash | $67.0M | $35.5M | $57.0M |
| Ending Cash | $35.5M | $57.0M | $37.3M |
Frequently Asked Questions
How does Black Diamond Therapeutics, Inc. make money?
The company operates primarily as a clinical-stage biotechnology entity without commercial revenue streams, deriving its value from its proprietary drug discovery platform, ongoing research and development expenditures, and potential future licensing or partnership agreements to fund operations.
What are the main risks for BDTX?
Significant risk of failure due to the early-stage nature of its pipeline assets which lack commercial revenue, heavy reliance on external financing given the substantial cash burn rate exceeding $69M annually, potential for regulatory setbacks in rare disease indications, and the high volatility inherent in clinical-stage biotechnology valuations.
What is BDTX's competitive advantage?
Black Diamond possesses a specialized expertise in rare disease therapeutics, offers a differentiated proprietary asset portfolio addressing unmet medical needs, and maintains operational efficiency through a lean organizational structure that minimizes capital expenditure while maximizing R&D output.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.